• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Liang Zhijun

    1/26/24 4:31:07 PM ET
    $ANPC
    Medical Specialities
    Health Care
    Get the next $ANPC alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Liang Zhijun

    (Last) (First) (Middle)
    C/O FRESH2 GROUP LIMITED
    650 5TH AVE STE 2416

    (Street)
    NEW YORK NY 10019-6108

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    01/01/2024
    3. Issuer Name and Ticker or Trading Symbol
    Fresh2 Group Ltd [ FRES ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Zhijun Liang 01/26/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ANPC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ANPC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ANPC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fresh2 Group Ltd. Announces Nasdaq Ticker Symbol Change from 'ANPC' to 'FRES'

      Ticker symbol change effective at the market open May 22, 2023 NEW YORK, May 19, 2023 /PRNewswire/ -- Fresh2 Group Ltd., formerly AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of  a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that its ticker symbol on the Nasdaq Stock Market ("Nasdaq") will change to "FRES" effective at the open of market trading on May 22, 2023 following the Company's name change from AnPac Bio-Medical Science Co., Ltd to Fresh2 Group Ltd. The Company has tra

      5/19/23 12:55:00 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • Fresh2 Files Annual Report on Form 20-F for Fiscal Year 2022

      NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd., "Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, today announced that it filed its annual report on Form 20-F for the fiscal year ended December 31, 2022, with the U.S. Securities and Exchange Commission (the "SEC") on May 16, 2023. The annual report on Form 20-F can be accessed on the SEC's website at http://www.sec.gov and the Company's investor rela

      5/16/23 5:00:00 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • Fresh2 Reports Fiscal Year 2022 Annual Financial Results

      NEW YORK, May 16, 2023 /PRNewswire/ -- Fresh2 Group Limited (Formerly AnPac Bio-Medical Science Co., Ltd. ,"Fresh2," the "Company" or "we") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and entering into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced today its annual financial results for the year ended December 31, 2022. Financial Highlights for Fiscal Year 2022 Total revenues were RMB12.0 million (US$1.7 million) in the year ended December 31, 2022, a decrease of 33.0% from RMB18.0 million in the year ended December 31, 2021.  Gross margi

      5/16/23 4:15:00 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Liang Zhijun

      3 - Fresh2 Group Ltd (0001786511) (Issuer)

      1/26/24 4:31:07 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Zhao Zhigang

      3 - Fresh2 Group Ltd (0001786511) (Issuer)

      1/26/24 4:29:59 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Li Xiaoyu

      3 - Fresh2 Group Ltd (0001786511) (Issuer)

      1/26/24 4:28:09 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by AnPac Bio-Medical Science Co. Ltd.

      SC 13D - Fresh2 Group Ltd (0001786511) (Subject)

      7/27/23 4:10:19 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by AnPac Bio-Medical Science Co. Ltd.

      SC 13G - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)

      3/24/23 6:09:00 AM ET
      $ANPC
      Medical Specialities
      Health Care
    • SEC Form SC 13D/A filed by AnPac Bio-Medical Science Co. Ltd. (Amendment)

      SC 13D/A - AnPac Bio-Medical Science Co., Ltd. (0001786511) (Subject)

      10/12/22 4:45:23 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    SEC Filings

    See more
    • AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Fresh2 Group Ltd (0001786511) (Filer)

      2/16/24 4:36:43 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Fresh2 Group Ltd (0001786511) (Filer)

      2/1/24 4:01:33 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio-Medical Science Co. Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits

      8-K - Fresh2 Group Ltd (0001786511) (Filer)

      1/29/24 5:29:36 PM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Financials

    Live finance-specific insights

    See more
    • AnPac Bio-Medical Science Acquires GISN (HK) LIMITED, a Technical Solution and Outsourcing Consulting Services Provider

      NEW YORK, Feb. 15, 2023 /PRNewswire/ -- AnPac Bio-Medical Science Co., Ltd. (the "Company") (NASDAQ:ANPC), a company with operations in the United States and China focused on early cancer screening and detection and plans to enter into the operation of a business-to-business e-commerce food platform focused on the sale of Asian sourced food products, announced the closing of the acquisition of GISN (HK) LIMITED ("GISN"), a technical solution and outsourcing consulting services provider focused on the digital, internet and Web 3 business transformation for start-ups and traditional enterprises. This acquisition is a critical initiative for the Company to improve the efficiency of its e-commer

      2/15/23 8:00:00 AM ET
      $ANPC
      Medical Specialities
      Health Care

    $ANPC
    Leadership Updates

    Live Leadership Updates

    See more
    • AnPac Bio Announces Appointment of New Directors and Co-Chief Executive Officer

      PHILADELPHIA, Aug. 05, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that effective August 2, 2022, the board of directors appointed Jiawen Kang as a member of the board of directors of the Company (the "Board") and a member of the Audit Committee and Nominating Committee. On that date, the Company also appointed Yuyang Cui as (a) Co-Chairman of the Board and (b) Co-Chief Executive Officer of the Company. As Co-CEO of the Company, Yuyang Cui will be primarily responsible for (i) searching and presentin

      8/5/22 4:45:00 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio Approved Written Resolutions of a Majority of the Members Addressing the Removal of Directors and Officers, Re-designation of Officers, and Change of Members of the Committees

      PHILADELPHIA, July 18, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that the Company's Members approved Written Resolutions of a Majority of the Members (the "Resolutions") on July 14, 2022 addressing the removal of directors and officers, re-designation of officers, and change of members of the committees. The Resolutions were approved by 69.29% of the total voting power of the Company entitled to vote at a general meeting in accordance with British Virgin Islands law, which allows Member's resolution

      7/18/22 6:39:14 PM ET
      $ANPC
      Medical Specialities
      Health Care
    • AnPac Bio Appoints Dr. Aidong Chen as New Chief Executive Officer and Chairman of the Board and Miss Sheng Liu as a New Board Member

      PHILADELPHIA, April 08, 2022 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. ("AnPac Bio," the "Company" or "we") (ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection, announced that Dr. Aidong Chen has joined the Company as its board director, Chief Executive Officer and Chairman of the Board of Directors. Dr. Aidong Chen has been a practicing physician and researcher for over 10 years. He has received over 20 global patents on his work and published 91 papers over his career. Dr. Chen has been affiliated with many leading hospitals, including Yijishan Hospital, and Nanjing Medical University. He has replace

      4/8/22 9:12:52 PM ET
      $ANPC
      Medical Specialities
      Health Care